Ritholtz Wealth Management Raises Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Ritholtz Wealth Management lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 16.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,894 shares of the pharmaceutical company’s stock after acquiring an additional 264 shares during the period. Ritholtz Wealth Management’s holdings in Vertex Pharmaceuticals were worth $771,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fortitude Family Office LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $30,000. ST Germain D J Co. Inc. bought a new stake in Vertex Pharmaceuticals in the second quarter worth $26,000. OFI Invest Asset Management purchased a new position in Vertex Pharmaceuticals during the third quarter worth $25,000. Cornerstone Planning Group LLC purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at $33,000. Finally, NBC Securities Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth about $34,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $418.01 on Friday. The company has a market cap of $107.98 billion, a P/E ratio of 30.09, a PEG ratio of 2.28 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The stock’s 50-day moving average is $422.13 and its 200 day moving average is $391.73. Vertex Pharmaceuticals Incorporated has a 1-year low of $310.90 and a 1-year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the previous year, the firm earned $3.33 EPS. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on VRTX shares. Barclays increased their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Royal Bank of Canada boosted their price objective on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a report on Tuesday, February 6th. JPMorgan Chase & Co. lifted their target price on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Canaccord Genuity Group cut shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and upped their price target for the stock from $332.00 to $379.00 in a report on Wednesday, January 24th. Finally, Wells Fargo & Company lifted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $420.48.

View Our Latest Stock Report on Vertex Pharmaceuticals

Insider Activity

In related news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Chairman Jeffrey M. Leiden sold 6,648 shares of Vertex Pharmaceuticals stock in a transaction on Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the completion of the sale, the chairman now directly owns 2,423 shares in the company, valued at $1,015,406.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 354 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the transaction, the executive vice president now owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,029 shares of company stock worth $7,989,227. Insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Recommended Stories

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.